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Abstract 
Aims: Experimental Autoimmune Myocarditis (EAM) model mirrors important mechanisms of 
inflammatory dilated cardiomyopathy (iDCM). In EAM, inflammatory CD133+ progenitors are a major 
cellular source of cardiac myofibroblasts in post-inflammatory myocardium. We hypothesized that 
exogenous delivery of Macrophage-Colony Stimulating Factor (M-CSF) can stimulate macrophage lineage 
differentiation of inflammatory progenitors and therefore prevent their naturally occurring myofibroblast 
fate in EAM.  
Methods and Results: EAM was induced in wild-type (BALB/c) and Nitric oxide synthase 2 deficient 
(Nos2−/−) mice and CD133+ progenitors were isolated from inflamed hearts. In vitro, M-CSF converted 
inflammatory CD133+ progenitors into nitric oxide-producing F4/80+ macrophages and prevented TGF-β-
mediated myofibroblast differentiation.  Importantly, only a subset of heart-infiltrating CD133+ progenitors 
expresses macrophage-specific antigen F4/80 in EAM. These CD133+/F4/80hi cells show impaired 
myofibrogenic potential compared to CD133+/F4/80− cells. M-CSF treatment of wild-type mice with EAM 
at the peak of disease markedly increased CD133+/F4/80hi cells in the myocardium, and CD133+ progenitors 
isolated from M-CSF-treated mice failed to differentiate into myofibroblasts. In contrast, M-CSF was not 
effective in converting CD133+ progenitors from inflamed hearts of Nos2−/− mice into macrophages, and M-
CSF treatment did not result in increased CD133+/F4/80hi cell population in hearts of Nos2−/− mice. 
Accordingly, M-CSF prevented post-inflammatory fibrosis and left ventricular dysfunction in wild-type but 
not in Nos2−/− mice.  
Conclusions: Active and NOS2-dependent induction of macrophage lineage differentiation abrogates the 
myofibrogenic potential of heart-infiltrating CD133+ progenitors. Modulating the in vivo differentiation fate 
of specific progenitors might become a novel approach for the treatment of inflammatory heart diseases. 
 
Key words: experimental autoimmune myocarditis, CD133 progenitor, M-CSF, myofibroblast, 
macrophage, nitric oxide synthase 2 
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Introduction 
 
Inflammatory dilated cardiomyopathy (iDCM) is an important cause of heart failure and sudden 
death in children and young patients1. Progressive cardiac dilation and fibrosis are hallmarks of iDCM in 
humans. iDCM refers to an end stage heart failure phenotype which often results from virus-triggered 
myocarditis2. Both, clinical observations and animal experiments suggest that infection-triggered 
autoimmunity plays an important role in iDCM3. Heart-specific autoimmune responses are a consequence of 
the lack of T cell tolerance to heart-specific alpha-myosin heavy chain (αMyHC) in mice and in humans4. 
Experimental autoimmune myocarditis (EAM) is a CD4+ T cell-mediated mouse model of iDCM. 
In susceptible mouse strains, EAM is commonly induced after immunization with αMyHC peptide together 
with a strong adjuvant4. In BALB/c mice, the extent of cardiac infiltrates peaks three weeks after 
immunization. Inflammatory infiltrates largely resolve thereafter, but the process of pathological 
remodelling continues and many mice develop an end stage heart failure phenotype, including ventricular 
dilation, myocardial fibrosis and heart failure on follow-up5.  
At the peak of EAM, inflammatory cells, including granulocytes, monocytes, macrophages, T cells, 
B cells, and CD133+ progenitors infiltrate the myocardium4, 6. CD133 (prominin-1) and its human 
orthologue, AC133, are often expressed on primitive cell populations including hematopoietic stem cells. In 
EAM, bone marrow-derived CD133+ progenitors represent the major cellular source of collagen-producing 
fibroblasts involved in the progressive Transforming Growth Factor-beta (TGF-β)-mediated cardiac 
remodelling6, which reflects the transition from acute inflammation into the typical end stage heart failure 
phenotype.  
Macrophages represent another important heart-infiltrating cell subset in EAM7. In mice, 
macrophages commonly express the F4/80 antigen. Their role in disease pathogenesis, however, remains 
controversial. So far, the nitric oxide synthase 2 (NOS2)-expressing M1 macrophage subset had been 
considered to contribute to disease progression7, 8, On the other hand, nitric oxide also acts as a strong 
immunosuppressive molecule preventing EAM development via induction of T cell apoptosis6. Alternatively 
activated M2 macrophages, are considered to promote resolution of inflammation and reduce disease 
severity7-9.   A
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Macrophage-colony stimulating factor (M-CSF) is one of the key cytokines regulating immune 
responses and reparative processes in many inflammatory and cardiovascular disorders10, 11. M-CSF plays a 
pivotal role in differentiation and maturation of the macrophage myeloid lineage12. Mice lacking functional 
M-CSF show macrophage deficiency, reduced phagocytosis and strongly impaired nitric oxide production13. 
In animal models of ischemic heart failure and viral myocarditis, M-CSF treatment improves cardiac 
function14, 15,16, but the mechanism is still unclear. 
We hypothesize that altering the in vivo fate of inflammatory progenitors by selectively promoting 
macrophage lineage differentiation, may protect from myofibroblast accumulation and cardiac fibrosis in 
EAM. In fact, M-CSF induced conversion of heart-infiltrating CD133+ progenitors into F4/80+ macrophages 
and prevented their myofibroblast differentiation in the post-inflammatory phase of EAM. Moreover, our 
data points to critical role of NOS2 and nitric oxide in M-CSF-dependent macrophage lineage differentiation 
of inflammatory CD133+ progenitors. Thus, we demonstrate how exogenous cytokine treatments may 
change the default differentiation fate of inflammatory progenitors and can prevent pathological tissue 
remodelling in iDCM.
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Methods 
 
Mice  
BALB/c (n=250) and Nos2−/− (n=50) mice on BALB/c background were used in this study. Animal 
experiments were performed in accordance with the Swiss federal law and with the Guide for the Care and 
Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication, 8th Edition, 
2011). All animal experiments were approved by the Cantonal Veterinary Office in Zürich. 
 
EAM induction and cytokine treatments 
Mice were injected subcutaneously with 150 µg of αMyHC (Ac-RSLKLMATLFSTYASADR-OH; Caslo) 
peptide emulsified 1:1 with Complete Freund's Adjuvant (CFA, Difco) on days 0 and 7. 200 µg/kg M-CSF 
(Peprotech) were intravenously injected 5x every second day between days 21-29 or days 40-48 of EAM. 
Control mice received solvent only. 
 
Histopathology and Immunocytochemistry 
Hearts were formalin-fixed and paraffin-embedded. Heart sections were stained with rat anti-mouse CD45  
(BD Bioscience), rabbit anti-mouse CD3 (Neomarkers), rat anti-mouse F4/80 (BMA biomedicals) and rabbit 
anti-rat IgG (Abcam) antibodies, and with Bond Polymer Refine Detection kit using BOND-MAX system 
(both Leica). Masson’s Trichrom staining was used to detect fibrosis. Immunopositive cells and fibrotic 
areas were quantified using analySIS FIVE software (Olympus). 
 
Echocardiography  
Mice were lightly anesthetized with 1-1.5% isoflurane, maintaining heart rate at 400-500 beats per minute. 
Transthoracic echocardiography was performed using a 30 MHz probe and the Vevo 770 Ultrasound system 
(VisualSonics) as described17 and in Supplementary Material.  
 
Cell cultures 
Myocarditis-positive hearts were perfused, dissected and digested with Liberase Blendzyme (Roche) for 45 A
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min at 37˚C and tissue suspensions were passed sequentially through 70 µm and 40 µm cell strainers. 
Cardiomyocytes were separated by low speed centrifugation (50 g, 2 min). CD133+ cells were isolated by 
positive selection using anti-CD133-PE antibody (eBioscience) and magnetic anti-PE-microbeads (Miltenyi) 
or using FACS.  Enriched CD133+ cells were plated onto gelatine-coated cell culture plates and cultured in 
the Iscove's Modified Dulbecco's Medium supplemented with 20% foetal bovine serum, 1:100 
penicillin/streptomycin, 100 mM non-essential amino acids, 100 mM sodium pyruvate and 50mM β-
mercaptoethanol (all Invitrogen). Macrophage differentiation was induced with 10 ng/mL M-CSF, and 
fibroblast differentiation with 10 ng/mL TGF-β (both PeproTech). 
 
Flow cytometry and cell sorting 
Single cell suspensions were prepared from digested hearts and cultured cells. Cells were incubated 30 min 
on ice with the appropriate combination of fluorochrome- or biotin-conjugated antibodies. The following 
antibodies were used: anti-CD45-FITC, anti-CD45-PE, anti-NOS2-FITC (all BD Bioscience), anti-CD133-
PE, anti-F4/80-PE (both eBioscience), biotin-conjugated anti-F4/80 (Cedarlane), anti-CD16/32 (Miltenyi), 
anti-CD206 (Biolegend), anti-CD301 (Serotec), anti-CD133 (eBioscience). Streptavidin-APC (BD 
Bioscience) was used to detect biotin-conjugated antibodies. Cells were analysed with the FACSCanto 
analyser (BD Bioscience) and FlowJo software (Tree Star). In some experiments, cells were sorted with 
FACSAria III (BD Bioscience). 
 
Quantitative RT-PCR 
Total RNA was isolated using RNeasy micro kit (Qiagen). cDNAs were amplified using the Power SYBR 
Green PCR Master Mix (Applied Biosystems) and oligonucleotides complementary to transcripts of the 
analyzed genes using the 7500 Fast Real-Time PCR System (Applied Biosystems). The following 
oligonucleotides were used in this study: αSMA (Acta2): 5’-cgctgtcaggaaccctgaga-3’, 5’-
cgaagccggccttacaga-3’; collagen I (Col1a1): 5’-gatgacgtgcaatgcaatgaa-3’, 5’-ccctcgactcctacatcttctga-
3’; fibronectin (Fn1): 5’-taccaaggtcaatccacacccc-3’, 5’-cagatggcaaaagaaagcagagg-3’; gapdh (Gapdh): 5’-
ctgcaccaccaactgcttagc-3’, 5’-ggcatggactgtggtcatgag-3’. Transcript levels of gapdh were used as endogenous 
reference, and relative gene expression was analyzed using the 2-∆∆Ct method. A
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 Immunohistochemistry and phagocytosis assays 
Cells were cultured on gelatine-coated cover slips and fixed with 4% paraformaldehyde or methanol:acetone 
(7:3). 1% bovine serum albumin was used as blocking solution. The following antibodies were used: mouse 
IgG anti-αSMA (Sigma), rabbit IgG anti-fibronectin (Milipore), AlexaFluor488 anti-mouse IgG and 
AlexaFluor546 anti-rabbit IgG 1:600 (both Invitrogen). DAPI was used to label nuclei. Alexa Fluor 488-
conjugated Escherichia coli BioParticles (Invitrogen) were used according to manufacturer’s 
recommendations. Immunofluorescence was analysed using the Olympus BX51 fluorescence microscope. 
 
Statistics 
Normally distributed data were analysed by unpaired, two-tailed Student’s t-test and by one-way ANOVA 
followed by Bonferroni post-hoc test. Severity scores were analysed by the one-way Kruskal-Wallis 
analysis. For correlation analysis, Pearson's correlation coefficient was calculated. All analyses were 
computed using GraphPad Prism 5 software. Differences were considered as statistically significant for 
p<0.05. 
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Results 
 
M-CSF converts heart-infiltrating CD133+ progenitors into functional F4/80+ macrophages, and 
prevents TGF-β-induced myofibroblast differentiation in vitro.  
BALB/c mice receiving two subcutaneous injections of αMyHC/CFA at days 0 and 7 develop 
severe myocarditis at day 21. At this stage, CD133+ progenitors represent about 30% of all CD45+ 
inflammatory cells in the heart6. To assess the differentiation capacity of these cells at the peak of disease, 
CD133+ cells were isolated from diseased hearts at day 21 of EAM, plated and expanded for two weeks in 
vitro. Expanded cells were cultured in the presence or absence of M-CSF or TGF-β for additional 14 days. 
In the presence of TGF-β, CD133+ cells differentiated into myofibroblasts, positive for αSMA and 
fibronectin (Fig. 1A-B). In contrast, addition of M-CSF failed to trigger myofibroblast differentiation (Fig. 
1A-B) and pre-treatment of CD133+ cells with M-CSF for 3 days prevented TGF-β-triggered myofibroblast 
formation (Fig. 1C-D). 
In cytokine-free cultures, most expanded cells remained positive for CD133 and were mainly 
negative for macrophage marker F4/80 (Supplementary Figure 1A-B). In the presence of M-CSF, however, 
CD133 expression was reduced (Supplementary Figure 1A) and cells up-regulated F4/80, CD11b and 
CD16/32, suggesting macrophage lineage differentiation (Supplementary Figure 1B-D). Cells cultured with 
M-CSF developed into fully active macrophages producing NOS2, secreting nitric oxide and phagocyting 
E.coli bacteria (Supplementary Figure 1E,F,J). Of note, M-CSF treatment did not affect expression of 
markers characteristic for alternatively activated M2 macrophages (CD206, CD301, Supplementary Figure 
1G-H) or markers characteristic for granulocytes or dendritic cells, i.e. Gr-1 (Ly6C, Supplementary Figure 
1I), MHC class II and CD11c (not shown). 
To address the immunomodulating potential of CD133+ progenitors and CD133+-derived M-CSF-
differentiated macrophages we co-cultured them with αMyHC-reactive Th17 cell lines in the presence of 
αMyHC-pulsed irradiated splenocytes as antigen presenting cells. On irradiated splenocytes, αMyHC-
reactive CD4+ T cells proliferated rapidly. In the presence of CD133+ progenitors or M-CSF-differentiated 
macrophages, however, proliferation was completely abolished (Supplementary Figure 2A). Further, we 
induced EAM in BALB/c mice and additionally administrated intravenously 2x106 of either in vitro A
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expanded CD133+ progenitors or CD133+-derived mature macrophages at day 7 after EAM induction and 
analysed myocarditis severity at day 21. In animals treated with both, CD133+ progenitors and M-CSF-
differentiated macrophages practically no myocarditis was observed compared to sham treated mice 
(Supplementary Figure 2B). In contrast, administration of M-CSF-differentiated macrophages expanded 
from Nos2−/− mice failed to protect from myocarditis (Supplementary Figure 2C). These latter findings 
confirm the protective and NOS2-dependent role of CD133+-derived M-CSF-differentiated macrophages in 
EAM. 
 
M-CSF treatment promotes accumulation of F4/80+ macrophages in the post-inflammatory heart  
At day 21, inflamed hearts contained a substantial pool of CD133+ progenitors, but fibrosis was not 
evident at this time point. As illustrated above, M-CSF effectively directs CD133+ progenitors into 
functional macrophages and prevents their myofibroblast differentiation. We therefore analysed how 
systemic M-CSF treatment of αMyHC/CFA-immunized mice affects the pattern of heart-infiltrating cell 
subsets. Accordingly, αMyHC/CFA-immunized mice received M-CSF injections between days 21-29 of 
EAM (Supplementary figure 3A). Three days after the first M-CSF injection, we observed significantly 
increased number of F4/80+ and CD133+ cells in the myocardium of M-CSF treated mice (day 24, Figure 
2A-B). Immunopositive F4/80+ macrophages in the myocardium decreased over time and remained at low 
numbers at day 40 (Figure 2A; Supplementary Figure 4A-B). M-CSF treatments, however, did not affect the 
expression of CD16/32, CD206 and CD301 in inflammatory macrophages (Figure 2E-G). Instead, we 
observed significantly increased NOS2 on F4/80+ cells in the heart after M-CSF treatment of wild-type mice 
(Figure 2D).  
 
M-CSF inhibits formation of myofibroblasts from inflammatory CD133+ progenitors in EAM 
Heart-infiltrating CD133+ progenitors represent the major cellular source of myofibroblasts in post-
inflammatory EAM6. At day 24 of EAM, we sorted inflammatory (CD45-positive) CD133+/F4/80− and 
CD133+/F4/80hi cells from the inflamed myocardium of BALB/c mice and found elevated levels of 
myofibroblast-specific genes in CD133+ cells negative for F4/80 (Figure 3A-B). These findings suggest that 
CD133+/F4/80− rather than CD133+/F4/80hi cells contribute to fibrogenesis in post-inflammatory EAM.  A
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10 
M-CSF-stimulated CD133+ progenitors acquired a functional macrophage phenotype within 3 days 
in vitro (Figure 2H). We therefore analysed F4/80 expression on heart-infiltrating CD133+ progenitors in M-
CSF-treated mice. We found that heart-infiltrating CD133+/CD45+ cells of M-CSF-treated mice had marked 
higher F4/80 at day 24 (i.e. 3 days after the cytokine treatment, Figure 3C-D). Next, we sorted heart-
infiltrating CD133+/CD45+ cells from PBS- and M-CSF-treated mice and found reduced mRNA levels of 
myofibroblast-specific genes in the M-CSF-treated group (Figure 3E). Furthermore, sorted heart-infiltrating 
CD133+/CD45+ cells from both groups were plated and cultured in the presence of TGF-β for 10 days. 
CD133+/CD45+ cells isolated from the myocardium of M-CSF-treated mice failed to differentiate into 
αSMA- and fibronectin-expressing myofibroblasts (Figure 3F).  
 
NOS2 controls M-CSF-dependent macrophage differentiation of heart-infiltrating CD133+ 
progenitors  
F4/80hi macrophages derived from CD133+ progenitors up-regulate NOS2 and produce nitric oxide. 
We therefore addressed the role of NOS2 in the macrophage differentiation processes. Accordingly, CD133+ 
progenitors were isolated at day 21 after immunization from inflamed hearts of wild-type or Nos2−/− mice 
and cultivated in the presence of M-CSF. Nos2−/− CD133+ progenitors showed reduced F4/80 and CD14 
expression and were functionally impaired as indicated by reduced E.coli phagocytosis (Figure 4A-E). To 
determine whether macrophage differentiation was mediated by NOS activity, CD133+ progenitors isolated 
from inflamed hearts of BALB/c mice were cultured for 3 days in the presence of M-CSF with or without L-
NAME, a non-specific NOS inhibitor. Cells cultured with L-NAME showed significantly reduced E.coli 
phagocytosis (Figure 4F) and reduced nitric oxide levels (Figure 4G). 
 
M-CSF treatment prevents cardiac fibrosis and left ventricular dysfunction in EAM 
M-CSF prevents TGF-β-mediated myofibroblast differentiation and promotes formation of 
macrophages from inflammatory CD133+ progenitors. Given that CD133+ progenitors represent the major 
source for myofibroblasts in EAM, we addressed whether M-CSF treatment reduces fibrogenesis in the post-
inflammatory heart. Accordingly, we treated αMyHC/CFA-immunized mice with M-CSF between days 21-
29 or 40-48 of EAM, and analysed the hearts at day 40 and 60 respectively (Supplementary figure 3A). As A
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illustrated in the Figure 5, M-CSF treatment completely prevented accumulation of fibroblasts in the post-
inflammatory heart (Figure 5A-C; Supplementary figure 4B). Of note, M-CSF treatment failed to attenuate 
fibrosis when delivered between days 40-48 (Figure 5A). These findings suggest that M-CSF treatment 
prevented the fibrotic process, but did not revert already established cardiac fibrosis.  
Relapses of inflammatory cells are quite common in autoimmune diseases. In BALB/c mice, we 
observed spontaneous inflammatory relapses 40 days after the first immunization (Figure 5D-E). During 
relapses, CD45+ inflammatory cells were mainly detected in the pericardium and largely represented CD3+ T 
lymphocytes (Figure 5D-E, Supplementary figure 3C). Interestingly, M-CSF treatment between days 21-29 
inhibited relapses in αMyHC/CFA-immunized mice as reflected by reduced numbers of CD45+ and CD3+ T 
cells in the myocardium at day 40 (Figure 5D-E; Supplementary figure 3C). 
Cardiac fibrosis parallels both, diastolic dysfunction, and reduced cardiac contractility. Not all 
immunized mice develop severe myocarditis. Consequently the extent of post-inflammatory fibrosis varies 
in the EAM model. In our series, 11 out of 20 αMyHC/CFA-immunized BALB/c mice showed substantial 
fibrosis (>2% of total heart area) on day 40. At this time point, echocardiography revealed reduced ejection 
fraction and fractional shortening in mice with significant fibrosis (Figure 5F). In addition, the extent of 
fibrosis correlated with increased mass, systolic and diastolic volume and isovolumetric contraction time of 
the left ventricle (Supplementary Figure 5A). Echocardiography of αMyHC/CFA-immunized and M-CSF-
treated mice showed unaffected cardiac function at day 40 (Figure 5F, Supplementary Figure 5E). 
Next, we immunized Nos2−/− mice with αMyHC/CFA and treated with M-CSF or PBS between 
days 21-29. αMyHC/CFA immunization resulted in myocarditis in Nos2−/− mice (not shown), but M-CSF 
treatment failed to affect fibrosis and heart functions during the post-inflammatory phase of EAM in Nos2−/− 
mice (Figure 6A, Supplementary figure 6). Similar results were observed if mice were M-CSF treated 
between days 14-22 (not shown). M-CSF treatment of Nos2−/− mice failed to increase the numbers of F4/80+ 
macrophages and CD133+ cells in the myocardium at day 24 and 40 of EAM (Figure 6A-C). We also 
observed no differences in F4/80 expression on inflammatory CD133+/CD45+ progenitors (not shown) and 
in the expression of M1/M2 markers on heart infiltrating F4/80+/CD45+ macrophages between M-CSF- and 
PBS-treated Nos2−/− mice (Figure 6D). 
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Discussion 
We previously reported that in the EAM model post-inflammatory pathogenic myofibroblasts 
mainly originate from heart-infiltrating CD133+ progenitor cells6. In line with our previous findings, herein 
we demonstrate that M-CSF controls the formation of anti-inflammatory macrophages from inflammatory 
CD133+ progenitors and prevents TGF-β-mediated differentiation into pathogenic myofibroblasts. Thus, our 
data suggest that in myocarditis, a significant pool of cells infiltrating the myocardium at the peak of disease 
represent non-committed progenitors.  
From a clinical perspective it is important that the differentiation fate of multipotent, non-
committed precursor cells infiltrating the myocardium, can be modulated via specific cytokine signalling in 
a controlled fashion. M-CSF is a key cytokine guiding macrophage differentiation in vitro8 and in vivo18. In 
EAM, M-CSF treatment up-regulated F4/80 expression on CD133+ inflammatory progenitors promoting 
macrophage differentiation. In untreated mice, however, heart-infiltrating CD133+ progenitors spontaneously 
differentiate into pathogenic myofibroblasts. To our knowledge, this is the first report describing the change 
of in vivo fate of inflammatory progenitors naturally present in the inflamed organ. So far, it has been 
described that M-CSF treatment improved cardiac function in a viral model of myocarditis16, after 
myocardial infarction14, 15, 19 and in the ischemia-reperfusion model20. Similar to our findings, M-CSF 
treatment promoted monocyte/macrophage accumulation in the heart after myocardial infarction14, 15 or virus 
inoculation16. 
Myocardial fibrosis plays a dual role in remodelling after cardiac injury. On one hand, it is a 
prerequisite for wound healing, as in case of ischemic injuries, for example. On the other hand, it contributes 
to ventricular stiffening and typical pathological remodelling in heart failure. Our previous and current data 
clearly show that excessive cardiac fibrosis parallels impaired cardiac function in EAM17. Thus, preserved 
left ventricular function in M-CSF-treated mice results primarily from reduced myofibroblast differentiation, 
rather than protective macrophage activity. We propose that the conversion of inflammatory progenitors into 
functional macrophages, instead of myofibroblasts, represent a key mechanism explaining reduced 
fibrogenesis upon M-CSF treatment. However, we cannot rule out that M-CSF also activates other pathways 
inhibiting myocardial fibrogenesis. For example, M-CSF may protect cardiomyocytes from H2O2-induced 
death20. Moreover, M-CSF could affect extracellular matrix composition and levels of matrix A
cc
ep
te
d 
M
an
us
cr
ip
t
 at U
niversitaet Zuerich on N
ovem
ber 2, 2012
http://cardiovascres.oxfordjournals.org/
D
ow
nloaded from
 
metalloproteinases and cytokines/chemokines, which drastically alter the myocardial microenvironment. 
Nevertheless, we can exclude direct M-CSF-mediated effects on cardiac fibroblasts, because upon M-CSF 
treatment during the late post-inflammatory phase of the EAM (days 40-48), the fibrosis was not reverted.  
It has been proposed that differential macrophage activation defines protective and pathogenic 
functions. Accordingly, adoptive transfer of M1 macrophages promoted histological disease scores, whereas 
injection of M2 macrophages was largely protective in Coxackievirus-induced myocarditis9. Also most 
heart-infiltrating macrophages were classified as M2 macrophages expressing mannose receptor and Gr-1 in 
αMyHC/CFA- and Coxackievirus-induced myocarditis7, 21. However, macrophages expressing M1 marker 
NOS2 have been identified in myocarditis as well22. We critically analysed macrophages in the myocardium 
after the peak of disease, during the post-inflammatory phase of EAM, and detected both, M1- and M2-
specific markers. We were, however, unable to clearly delineate two distinct activation states. We assume 
that during EAM, heart-infiltrating macrophages were activated classically (M1) and alternatively (M2) at 
the same time. In fact, it is well known that T cells and other heart-infiltrating cells massively produce both, 
M1-activating IFN-γ as well as M2-activating IL-4 and IL-137. Importantly, M-CSF treatment did not affect 
the expression of M1 and M2 markers except of NOS2. M-CSF-induced macrophage accumulation in the 
post-inflammatory heart was not pathogenic in our model, because resolution of inflammation, defined by 
the extent of inflammatory cells was clearly M-CSF independent. Moreover, M-CSF-induced macrophages 
showed strong immunosuppressive activity in vitro and in vivo. We believe that accumulation of the 
immunosuppressive macrophages in M-CSF-treated mice protected from spontaneous T cell relapse. 
Nevertheless, we cannot, entirely rule out that M-CSF also mediates protective effects by acting on other 
target cells.  
We previously found that M-CSF-induced CD11b+ monocytes prevented EAM development and 
suppressed CD4+ T cell proliferation in a nitric oxide-dependent manner23. M-CSF treatment promoted 
inflammatory macrophages expressing NOS2 in EAM, We therefore hypothesized that macrophage-
produced nitric oxide might control both; T cell mediated early inflammation as well as post-inflammatory 
fibrosis in EAM. Indeed, mice lacking NOS2 or treated with nitric oxide inhibitors showed enhanced cardiac 
inflammation and fibrotic lesions in a model of Coxackievirus-induced myocarditis24, 25. Similarly, Nos2−/− 
mice also develop more severe myocarditis in the EAM model (Kania, Blyszczuk & Eriksson- unpublished A
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14 
observations). Nevertheless, we observed spontaneous resolution of inflammation in Nos2−/− mice, 
suggesting that NOS2 is not critically involved in the resolution of inflammation in the EAM model. 
Surprisingly, treatment of Nos2−/− mice with M-CSF failed to turn CD133+ progenitors into macrophages 
and to prevent fibrosis development. Furthermore, we showed that Nos2−/− CD133+ progenitors stimulated 
with M-CSF failed to generate functional macrophages. These results suggested that NOS2 was required for 
M-CSF-induced macrophage differentiation and maturation. Accordingly, NOS2 has been reported to 
control differentiation of human monoblasts26. Regulation of gene expressions by nitric oxide can explain 
requirement of NOS2 in this differentiation processes27. At this stage, we cannot, however, exclude that in 
Nos2−/− mice, heart-infiltrating CD133+ progenitors are committed toward fibroblast phenotype due to 
alerted cytokine expression profile in the myocardium. Based on our findings, we can assume that M-CSF 
stimulates nitric oxide production that, in turn, promotes macrophage differentiation of inflammatory 
progenitors.  
In summary, our data demonstrate that a single hematopoietic cytokine, such as M-CSF can 
modulate the in vivo fate of inflammatory CD133+ progenitors in a way to promote their differentiation into 
macrophages instead of myofibroblasts in the post-inflammatory phase of the EAM. Furthermore, our data 
suggest that mature inflammatory macrophages, in contrast to progenitor-derived fibroblasts, do not promote 
heart failure after acute myocarditis. These findings are in line with the clinical observation that fulminant 
myocarditis implies an excellent long-term prognosis whereas subacute myocarditis usually progresses to 
end stage heart failure28.  
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Figure legends 
Figure 1. M-CSF prevents differentiation of heart-infiltrating CD133+ progenitors into 
myofibroblasts.  
(A,B) Heart-infiltrating CD133+ cells were expanded from myocarditis-positive hearts at day 21 of EAM 
and stimulated without (control, white) or with 10 ng/mL M-CSF (gray), or 10 ng/mL TGF-β (black) for 14 
days. Relative mRNA expression of myofibroblast-specific fibronectin (Fn1), collagen I (Col1a1) and 
αSMA (Acta2) (A, n=5). Representative immunofluorescence and quantification analysis of αSMA (top) 
and fibronectin (bottom) in cultured cells (B, n=5).  
 (C,D) Expanded heart-infiltrating CD133+ cells (EAM d21) pre-treated for 3 days without (control, black) 
or with 10 ng/mL M-CSF (+M-CSF d-3, hatch), washed and stimulated with 10 ng/mL TGF-β for 14 days. 
Relative mRNA levels of myofibroblast-specific genes (C, n=5) and representative immunofluorescence and 
quantification analysis of αSMA (D, top) and fibronectin (D, bottom) are shown (n=5).  
*** p<0.001 (two-tailed Student’s t-test versus control), bar = 20µm. 
 
Figure 2. M-CSF treatment turns inflammatory CD133+ progenitors into F4/80+ macrophages in 
EAM.  
BALB/c mice were immunized with αMyHC/CFA at day 0 and 7, and treated with PBS or M-CSF between 
days 21-29. 
(A) Quantification of F4/80+ macrophages in the myocardium of PBS- (black) and M-CSF-treated (white) 
mice at day 24 (n=6), 28 (n=5) and 40 (n=20). Immunopositive cells were quantified per mm2 of heart 
tissue. 
(B) Flow cytometry analysis of CD133 and F4/80 on heart infiltrating CD45+-gated cells (left) in EAM. 
Quantification of CD133+ (left graph) and F4/80+ (right graph) cells gated on CD45+ infiltrates of PBS- 
(black) and M-CSF-treated (white) mice at day 24 (n=5) and 28 (n=5) of EAM. 
(C-G) Flow cytometry analysis of M1 and M2 activation markers on heart infiltrating CD45+/F4/80+-gated 
macrophages (left) in EAM. Mean fluorescence intensity (MFI) of membrane markers (CD16/32, CD206, 
CD301) and intracellular NOS2 expression gated on inflammatory macrophages of PBS- (black) and M-
CSF-treated (white) mice at day 24 (n=10) of EAM. (–) isotype controls, (+) antigen-specific antibodies. A
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 (H) Overlay of phase contrast (left and middle) or F4/80 expression (right, red) with E.coli bacteria (green) 
taken up in the phagocytosis assay of expanded heart-infiltrating CD133+ cells (isolated from heart at d21) 
stimulated with M-CSF for 1 (left) and 3 days (middle and right). Bar = 20µm. 
ns p>0.05, * p<0.05, ** p<0.01, *** p<0.001 (two-tailed Student’s t-test). 
 
Figure 3. M-CSF inhibits myofibroblast lineage differentiation of inflammatory CD133+ in EAM.  
(A) Representative flow cytometry analysis of CD133+ and F4/80 (right) gated on heart infiltrating CD45+ 
cells (left) at day 24 of EAM. Numbers indicate percentage of positive cells in the adjacent gates. 
(B) Heart-infiltrating CD45+/CD133+/F4/80− (white) and CD45+/CD133+/F4/80hi (black) cells were FACS 
sorted from myocarditis-positive hearts at day 24 of EAM. Relative mRNA levels of myofibroblast-specific 
genes are shown for 1 out of 2 independent experiments (n=5). 
(C) Representative flow cytometry analysis of CD133 and F4/80 gated on heart infiltrating CD45+/CD133+ 
progenitor cells (left) of PBS- (+PBS) and M-CSF-treated (+M-CSF) mice at day 24 of EAM. Staining with 
anti-CD45 and anit-CD133 and IgG control to anti-F4/80 antibodies (IgG control) was used to set the gates. 
Numbers indicate percentage of positive cells in the adjacent gates. 
(D) Quantification of F4/80hi (left) and F4/80− (right) cells gated of CD45+/CD133+ progenitor cells (gated 
as shown in C) of PBS- (black) and M-CSF-treated (white) mice at day 24 of EAM. 
(E,F) Heart-infiltrating CD45+/CD133+ cells were FACSorted from myocarditis-positive hearts at day 24 of 
EAM from control PBS-treated (black, +PBS) or M-CSF-treated (white, +M-CSF). A relative mRNA level 
of myofibroblast-specific genes of sorted cells is shown (E, n=5). In addition, sorted cells were plated and 
stimulated with 10 ng/mL TGF-β for 10 days. Representative immunofluorescence and quantification 
analysis of αSMA (F, top) and fibronectin (F, bottom) are shown (n=5).  
Bar = 20µm, ns p>0.05, * p<0.05, ** p<0.01, *** p<0.001 (two-tailed Student’s t-test). 
 
Figure 4. NOS2 is required for M-CSF-dependent macrophage lineage differentiation from CD133+ 
progenitors. 
(A-E) Expanded heart-infiltrating CD133+ cells (EAM d21) from wild-type BALB/c and Nos2−/− mice were 
stimulated with 10 ng/mL M-CSF for 3 days. (A) Representative flow cytometry analysis of expanded cells A
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using anti-CD133 (right) and IgG control (left) antibodies. Numbers indicate percentage of positive cells in 
the adjacent gates. Representative histogram analysis of macrophage specific antigens F4/80 (B), CD11b 
(C), CD14 (D), and E.coli bacteria taken up in the phagocytosis assay (E) on CD133+ cells (gated as shown 
in A). Isotype controls are displayed in grey. Numbers in histograms indicate mean fluorescence intensity 
(MFI). Bar graphs show quantification of the respective analyses for wild-type (black) and Nos2−/− (hatch) 
cells. n=5, (–) isotype controls, (+) antigen-specific antibodies or E.coli.  
 (F) Expanded heart-infiltrating CD133+ cells (EAM d21) from BALB/c (wild-type) mice were stimulated 
with 10 ng/mL M-CSF for 3 days in the absence (control) or presence of 2mM L-NAME (+L-NAME). 
Representative histogram analysis of E.coli bacteria uptake by CD133+ cells (gated as shown in A). Controls 
without E.coli are displayed in grey. Numbers in histograms indicate MFI. Bar graphs show quantification 
of the respective analyses in the absence (white) or presence of L-NAME (grey).  n=5, (–) control, (+) E.coli 
(G) Nitrite levels in supernatants of cultures stimulated with 0.1 µg/mL LPS for 24h. n = 4  
ns p>0.05, * p<0.05, ** p<0.01, *** p<0.001 (two-tailed Student’s t-test).  
 
Figure 5. M-CSF treatment attenuates myocardial fibrosis and prevents heart failure in EAM. 
BALB/c mice were immunized at day 0 and 7 with αMyHC/CFA and injected either with PBS (black) or 
M-CSF between days 21-29 (white) or days 40-48 (grey).  
(A) Fibrosis was evaluated in heart sections at day 24 (n=10), 28 (n=10), 40 (n=20) and 60 (n=6-8). The 
degree of fibrosis was analysed by Masson’s trichrome staining and calculated as percentage of the fibrotic 
area in heart sections.  
(B,C) The representative microphotographs of the myocardial tissue (d60) following PBS (B) or M-CSF (C) 
treatment between days 21-29 stained with Masson’s trichrome. Bar = 100 µm.  
 p values were computed using two-tailed Student’s t-test (A, d24, d28 and d40), one-way ANOVA (A, 
d60).  
(D-E) Quantification of CD45+ cells (defining all inflammatory infiltrates, D) and CD3+ cells (defining T 
lymphocytes, E) within the myocardium during EAM at day 24 (n=10), 28 (n=10), 40 (n=20) and 60 (n=6-8) 
after the first immunization. Immunopositive cells were quantified per mm2 of heart tissue.  
 (F) Echocardiographic parameters of healthy, untreated BALB/c mice (white) in comparison to A
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22 
αMyHC/CFA-immunised mice with <2% myocardial fibrosis (hatch, n=9), >2% myocardial fibrosis (black, 
n=11) and αMyHC/CFA-immunised mice treated with M-CSF at days 21-29 (grey, n=20).  
p values were computed using correlation analysis (F) and the one-way ANOVA (A,D,E). * p<0.05, ** 
p<0.01, *** p<0.001 for the respective group versus healthy controls (white) calculated with Bonferroni 
post-hoc test. 
 
Figure 6. M-CSF treatment fails to reduce fibrosis in Nos2−/− mice. 
Nos2−/− mice were immunized at day 0 and 7 with αMyHC/CFA and treated with PBS or M-CSF between 
days 21-29.  
(A,B) Quantification of fibrosis and F4/80+ macrophages in the myocardium of PBS- (black) and M-CSF-
treated (white) Nos2−/− mice at day 24 (A, n=5) and 40 (B, n=10) of EAM. F4/80+ cells were quantified per 
mm2 of heart tissue, and the degree of fibrosis was analysed by Masson’s trichrome staining.  
(C) Representative histograms of CD133 expression gated on heart infiltrating CD45+ inflammatory cells 
(left) of PBS- (+PBS) and M-CSF-treated (+M-CSF) Nos2−/− mice at day 24 of EAM. Isotype controls are 
displayed in grey. Numbers indicate percentage of positive cells in the presented histograms. Bar graphs 
show quantification of CD133+ and F4/80+ gated on CD45+ cells of PBS- (black) and M-CSF-treated (white) 
Nos2−/− mice (n=5). 
(D) Flow cytometry analysis of M1 and M2 activation markers in EAM. Quantification of mean 
fluorescence intensity (MFI) of membrane macrophage activation markers gated on heart infiltrating 
CD45+/F4/80+-gated macrophages (left) of PBS- (grey) and M-CSF-treated (hatch) Nos2−/− mice at day 24 of 
EAM (n=5). (–) isotype controls, (+) antigen-specific antibodies, ns p>0.05 (two-tailed Student’s t-test). 
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